Tranexamic Acid, Mortality, and Intracranial Hemorrhage Type in Moderate or Severe Traumatic Brain Injury

W Ian McKinley; Susan E Rowell; Ali Mansour; Lea Hoefer; Ann Polcari; Martin Schreiber; Andrew J Benjamin

doi:10.1001/jamasurg.2023.3848

Tranexamic Acid, Mortality, and Intracranial Hemorrhage Type in Moderate or Severe Traumatic Brain Injury

JAMA Surg. 2023 Nov 1;158(11):1222-1224. doi: 10.1001/jamasurg.2023.3848.

Authors

W Ian McKinley¹, Susan E Rowell¹, Ali Mansour¹, Lea Hoefer¹, Ann Polcari¹, Martin Schreiber², Andrew J Benjamin¹

Affiliations

¹ The University of Chicago, Chicago, Illinois.
² Oregon Health & Science University, Portland.

PMID: 37755726
PMCID: PMC10535002 (available on 2024-09-27)
DOI: 10.1001/jamasurg.2023.3848

No abstract available

Plain language summary

This cohort study examines the association of tranexamic acid administration with intracranial hemorrhage type, neurologic outcomes, and mortality in patients with traumatic brain injury.

MeSH terms

Antifibrinolytic Agents* / therapeutic use
Brain Injuries, Traumatic* / complications
Humans
Intracranial Hemorrhages
Tranexamic Acid* / therapeutic use

Substances

Tranexamic Acid
Antifibrinolytic Agents